Sexual Difficulties Common Among Young Adult Cancer Survivors, Study Finds

A new doctoral study from Sweden's Karolinska Institutet has found that sexual difficulties are common among young people who have survived cancer treatment. The nature and severity of those difficulties shift considerably based on cancer type and how intensively the patient was treated. Charlotta Bergström, a nurse and doctoral student at the Karolinska Institutet, led the research, which covered more than 1,000 patients.

The findings underscore the importance of addressing sexual health as a component of survivorship care. As companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) continue with their efforts toward developing the next generation of cancer treatments, understanding the long-term side effects is crucial. The study highlights that young adults, often assumed to be at lower risk for such issues, face significant challenges that can affect their quality of life.

Bergström's research analyzed data from over 1,000 young adults (ages 18-39) who had been treated for various cancers, including breast, testicular, and hematological malignancies. Participants reported on their sexual function, satisfaction, and distress. Results showed that about 50% of men and 60% of women experienced at least one sexual problem, such as erectile dysfunction, vaginal dryness, or low libido, often persisting years after treatment.

The type of cancer and treatment intensity were key factors. Patients who received high-dose chemotherapy or radiation to pelvic areas had higher rates of severe difficulties. For example, testicular cancer survivors often faced erectile dysfunction, while breast cancer survivors reported vaginal symptoms and decreased desire. The study also found that psychological factors, including anxiety and body image issues, compounded the physical effects.

These findings are particularly relevant for healthcare providers who may overlook sexual health in follow-up care. The study suggests that early assessment and intervention, such as counseling or medical therapies, could improve outcomes. As research progresses, companies like CNS Pharmaceuticals may contribute to treatments that minimize such side effects. The full study is available through Karolinska Institutet.